2019
MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer
Wang C, Liu Y, Guo W, Zhu X, Ahuja N, Fu T. MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer. Cancer Management And Research 2019, 11: 7337-7343. PMID: 31496795, PMCID: PMC6689138, DOI: 10.2147/cmar.s206731.Peer-Reviewed Original ResearchStage II colorectal cancerColorectal cancerFive-year overall survival rateStage II CRC patientsOverall survival rateCox regression analysisImportant prognostic variablesProximal colon tumorsCpG island methylator phenotype (CIMP) statusMicrotubule-associated protein tauCIMP-high tumorsPromoter CpG islandsCRC patientsWorse prognosisPoor prognosisPrognostic valuePrognostic markerPrognostic variablesPatientsHigh tumorSurvival rateAlzheimer's diseaseColon tumorsMultivariate analysisProtein tau
2012
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen
Jeschke J, Van Neste L, Glöckner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG, Ahuja N. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 2012, 7: 701-709. PMID: 22647880, DOI: 10.4161/epi.20445.Peer-Reviewed Original ResearchConceptsPoor overall survivalBreast cancerOverall survivalPrognosis predictionEffective biomarkersClinical prognostic variablesPrimary breast cancerDetection of BCFrequent methylated genesStrongest single markersSignificant prognosticatorBC patientsValidation cohortPrognostic variablesPrognostic signatureEarly detectionCancerBiomarkersPromoter hypermethylationMethylation changesTumor heterogeneityPrognosisSingle markerGene expression approachSurvival